Related Experiment Video

Updated: May 24, 2026

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
08:01

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

[Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia]

Nadaa Konstantinidis, Jovanka Kolarović, Nataša Kaćanski

    Srpski Arhiv Za Celokupno Lekarstvo
    |February 18, 2012
    PubMed

    Insights

    Allergic reactions to L-asparaginase (L-ASP) therapy for childhood acute lymphoblastic leukaemia (ALL) occur in 24% of patients. Risk factors include high-risk ALL protocols, intravenous administration, and re-exposure after a four-week break.

    Area of Science:

    • Pediatric Oncology
    • Clinical Pharmacology
    • Immunology

    Context:

    • L-asparaginase (L-ASP) is a cornerstone therapy for childhood acute lymphoblastic leukaemia (ALL).
    • Allergic reactions represent a significant challenge, potentially leading to treatment interruption.
    • Understanding risk factors is crucial for optimizing L-ASP administration and patient outcomes.

    Purpose:

    • To determine the prevalence and types of allergic reactions to L-ASP in pediatric ALL patients.
    • To identify potential risk factors associated with L-ASP-induced hypersensitivity.
    • To analyze the relationship between reaction onset, therapy phase, and administration method.

    Summary:

    • This study analyzed 70 pediatric ALL patients treated with L-ASP between 2000 and 2009.
    • Allergic reactions occurred in 24% of patients, primarily manifesting as urticaria, bronchospasm, or anaphylaxis.
    • Key risk factors identified were high-risk protocols, intravenous administration, and re-administration after a minimum four-week interval, particularly during reinduction phases.

    Impact:

    • Identifies specific patient subgroups and administration strategies associated with increased risk of L-ASP allergy.
    • Provides evidence to guide clinical decisions regarding L-ASP dosing and scheduling in pediatric ALL.
    • Informs the development of strategies to mitigate hypersensitivity reactions and ensure treatment continuity.
    Abstract

    More Related Videos

    In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)06:48

    In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

    Published on: August 1, 2025

    Related Concept Videos

    Allergic Reactions: Anaphylaxis01:30

    Allergic Reactions: Anaphylaxis

    Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
    Allergic Reactions02:06

    Allergic Reactions

    Overview
    Local Anesthetics: Adverse Effects01:12

    Local Anesthetics: Adverse Effects

    While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
    Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
    Allergic Drug Reactions01:27

    Allergic Drug Reactions

    Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
    Drug Toxicity: Allergic Reactions01:30

    Drug Toxicity: Allergic Reactions

    Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
    Antiasthma Drugs: Leukotriene Modifiers01:19

    Antiasthma Drugs: Leukotriene Modifiers

    Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
    Leukotriene modifiers work through two distinct mechanisms: